OncoMatch/Clinical Trials/NCT03710421
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
Is NCT03710421 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Cyclophosphamide and Fludarabine for recurrent plasma cell myeloma.
Treatment: Cyclophosphamide · Fludarabine — This phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor (CAR) T therapy after chemotherapy in treating patients who have CS1 positive multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Immune cells can be engineered to kill multiple myeloma cells by inserting a piece of deoxyribonucleic acid (DNA) into the immune cells using a lentiviral vector such as CS1, that allows them to recognize multiple myeloma cells. These engineered immune cells, CS1-CAR T cells, may kill multiple myeloma cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: SLAMF7 overexpression (CS1+)
confirmed CS1+ MM as evaluated by City of Hope (COH) Pathology Core
Prior therapy
Must have received: immunomodulatory agent
Must have received: proteasome inhibitor
Must have received: anti-cd38 antibody
Cannot have received: allogeneic stem cell transplantation
Lab requirements
Blood counts
Absolute neutrophil count >= 1000/uL (no transfusions/growth factors at screening); Hemoglobin >= 8 g/dl (no transfusions/growth factors at screening); Platelet count >= 50,000/uL (>= 30,000/uL if bone marrow plasma cells >= 50% of cellularity; no transfusions/growth factors at screening)
Kidney function
Serum creatinine <= 2.5 x ULN or estimated creatinine clearance >= 40 mL/min per Cockcroft-Gault formula, not on hemodialysis
Liver function
Total serum bilirubin <= 2.0 mg/dL (<= 3.0 mg/dL if Gilbert syndrome); AST < 2.5 x ULN; ALT < 2.5 x ULN
Cardiac function
Left ventricular ejection fraction >= 45% within 8 weeks before enrollment; O2 saturation >= 92%
Total serum bilirubin <= 2.0 mg/dL. Participants with Gilbert syndrome may be included if their total bilirubin is <= 3.0. AST < 2.5 x ULN. ALT < 2.5 x ULN. Serum creatinine <= 2.5 x ULN or estimated creatinine clearance of >= 40 mL/min per the Cockcroft-Gault formula, and the participant is not on hemodialysis. Absolute neutrophil count >= 1000/uL. Hemoglobin (Hb) >= 8 g/dl. Platelet count >= 50,000/uL (>= 30,000/uL if bone marrow plasma cells are >= 50% of cellularity). Left ventricular ejection fraction >= 45% within 8 weeks before enrollment. Oxygen (O2) saturation >= 92%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify